APA

Bousser M. G., Amarenco P., Chamorro A., Fisher M., Ford I., Fox K., Hennerici M. G., Mattle H. P. & Rothwell P. M. (20090722). Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. : Cerebrovascular diseases (Basel, Switzerland).

Chicago

Bousser M G, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici M G, Mattle H P and Rothwell P M. 20090722. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. : Cerebrovascular diseases (Basel, Switzerland).

Harvard

Bousser M. G., Amarenco P., Chamorro A., Fisher M., Ford I., Fox K., Hennerici M. G., Mattle H. P. and Rothwell P. M. (20090722). Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. : Cerebrovascular diseases (Basel, Switzerland).

MLA

Bousser M G, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici M G, Mattle H P and Rothwell P M. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. : Cerebrovascular diseases (Basel, Switzerland). 20090722.